GlassScriptPhysician profile
Mihaela Batke
NPI 1578593513
$4,489.35
in general payments reported to CMS, 2019-2025
25 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.72 · 2020: $166 · 2021: $279 · 2022: $699 · 2023: $683 · 2024: $1,419 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,279 · Education: $41.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,278.83 |
| Education | $41.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,538.90 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $440.07 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $376.90 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Janssen Pharmaceuticals, INC | $241.34 | 2021-2022 | |
| Pfizer INC. | $239.67 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $228.82 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.05 | 2022-2024 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $167.48 | 2024-2025 | Zenpep, Vowst |
| Intercept Pharmaceuticals, INC. | $124.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $123.94 | 2024 | Zeposia |
| Celgene Corporation | $117.71 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $110.07 | 2022-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $95.69 | 2022-2023 | Linzess |
| Ardelyx, INC. | $90.96 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $84.99 | 2024-2025 | Omvoh |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $81.01 | 2022-2023 | Dificid |
| Genzyme Corporation | $49.08 | 2025 | |
| Braintree Laboratories, INC. | $37.23 | 2022-2023 | Sutab |
| Madrigal Pharmaceuticals | $35.02 | 2024 | Resmetirom |
| Vivus LLC | $29.19 | 2023-2025 | Qsymia |
| Ipsen Biopharmaceuticals, INC | $21.90 | 2024 | Iqirvo |
| Convatec INC. | $20.28 | 2024 | |
| Medtronic, INC. | $17.20 | 2025 | Interstim |
| Novo Nordisk INC | $13.84 | 2025 | Wegovy |
| Organon LLC | $12.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mihaela Batke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.